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1. Introduction 
New onset atrial fibrillation is the most common rhythm disturbance in critically ill patients. 
Although it is frequently seen in critically ill patients, data regarding the aetiology and 
treatment are scarce. Extrapolating treatment regimes from non-critically ill patients is not 
recommended since there is a difference in aetiology of the arrhythmia.  In this chapter we will 
discuss the pathophysiology and treatment strategies of new onset atrial fibrillation in 
medical- and non-cardiac surgery critically ill patients, based on the latest available evidence.   
2. Pathophysiology 
In critically ill patients the underlying mechanism for developing atrial fibrillation might 
differ from the outpatients clinic. Electrolyte disorders, rapid fluid changes like bleeding on 
one site and fluid overload by rapid filling in case of sepsis on the other site are present in 
excess and perfect triggers that induce atrial fibrillation. Reduced left ventricular function is 
also associated with atrial fibrillation. In critically ill patients, especially patients with sepsis, 
myocardial depression can occur, therefore inducing heart failure and, as a consequence, a 
higher risk of atrial fibrillation. Also underlying cardiac ischemia, for example the results of 
tremendous physically exercise which sepsis is, but also as a results of previously known or 
unknown coronary artery disease, can induce atrial fibrillation.  
Recent studies have shown that elevated inflammatory biomarkers are associated with the 
development of atrial fibrillation. Inflammatory markers like C-reactive protein (CRP), high-
sensitivity CRP (hs-CRP) an interleukin-6 are elevated in both patients with paroxysmal as 
persistent atrial fibrillation (Chung et al 2001 Dernellis et al 2001, Gaudino et al 2003). Atrial 
fibrillation is also common in septic patients, (Salman et al 2008, Christians et al 2008) the 
incidence is even higher in patients with septic shock.  46% of patients with septic shock 
developed new onset atrial fibrillation, often with an increase in C-reactive protein (CRP) 
levels before the onset of atrial fibrillation. (Meierhenrich et al 2010)  As most critically ill 
patients have elevated inflammatory markers, they, therefore might be at risk for the 
development of atrial fibrillation (Sequin et al 2006). Furthermore, atrial fibrillation is also 
associated with local inflammation like pericarditis and myocarditis.   
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3. Treatment 
Evidence for the best treatment strategy in critically ill patients is scarce. There are only 4 
randomized controlled trials and furthermore 3 prospective follow-up studies who included 
mainly non-cardiac surgery and medical critically ill patients (table 1). However, since there 
is heterogeneity in not only patient selection, but also type of atrial arrhythmia and 
definition of treatment goals, these trials are not comparable and therefore the best 
treatment strategy based on these trials cannot be recommended. Even the question whether 
to treat or not critically ill patients with new onset atrial fibrillation has not been answered 
yet. Placebo controlled trials are lacking and, furthermore, spontaneous conversion is 
common in new onset atrial fibrillation, even in the setting of critically ill patients.  
 
RCT trials Number  
of patients  
Rhythm  Intervention  
Chapman  
1993 
24 AT Amiodarone  vs  Procainamide 
Barranco  
1994 
30 SVT Flecainide  vs Verapamil  
Moran  
1995 
42 SVT Magnesium vs  Amiodarone  
Balser  
1998 
64 SVT Esmolol vs Diltiazem   
Prospective    
Holt  
1989 
10 SVT Amiodarone  
Mayr  
2003 
37 SVT Direct current cardioversion  
Sleeswijk  
2008 
29 NAF Magnesium 
Amiodarone 
AT= atrial tachycardia 
SVT= supraventricular tachycardia  
PSVT= paroxysmal atrioventricular nodal reentrant tachycardia 
NAF= new onset atrial fibrillation   
A.fib= atrium fibrillation   
A.flut= atrium flutter 
Table 1.  
Despite the lack of evidence, it is common practice to treat atrial fibrillation in the ICU 
setting. Many physicians feel the need to restore sinus rhythm in critically ill patients with 
either electrical cardioversion, chemical conversion or a combination of these treatment 
strategies. These feelings are predominantly based on their experience in non-critically ill 
patients. However, critically ill patients differ from the general population, therefore,  
extrapolating treatment regimes and results are not justified and may even harm. For 
example, DC electrical cardioversion in patients with new onset atrial fibrillation has a 
success rate of over 90%, while the only study investigating DC electrical cardioversion in 
critically ill patients yields an initial success rate of 35 % and only 13,5% after 48 hours, 
(Mayr et al 2003) which data are comparable to control group e.g. spontaneous conversion. 
Guidelines recommend immediate cardioversion in hemodynamic unstable patients. 
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Although critically ill patients are often hemodynamic unstable, this is in most cases not 
directly the results of atrial fibrillation, but on the contrary, atrial fibrillation is often the 
result of hemodynamic instability. Therefore an approach with direct DC electrical 
cardioversion may not be suitable in the ICU setting.      
Although data are lacking, as mentioned before, most physicians tend to treat atrial 
fibrillation with rapid ventricular response in some way, therefore, the three cornerstones of 
treatment for atrial fibrillation include corrections of the underlying condition, rhythm or 
rate control and prevention of thrombo-embolic complications 
3.1 The underlying condition 
Whether treatment of the underlying condition may restore sinus rhythm or prevent 
recurrent atrial fibrillation, is not exactly known.  However, treatment of the underlying 
disease and correction of precipitating factors such as electrolyte disturbances, volume 
imbalance or hypoxia are part of the general treatment in the ICU setting and are treated 
anyway. By “simply” treating sepsis lots of triggers that may induce atrial fibrillation will be 
eliminated and in most cases the arrhythmia will convert spontaneously to sinus rhythm by 
correcting electrolyte disorders and major fluid changes. However, in some of these 
patients, atrial fibrillation direct contribute to further hemodynamic deterioration of the 
patient and therefore should be treated as soon as possible. Since, as mentioned before, 
triggers are available in excess and also cannot always be removed, conversion to sinus 
rhythm might be a rather optimistic treatment goal, which means, conversion might be 
possible, but subsequently remaining sinus rhythm might be the Achilles’ heel of this 
treatment strategy. Therefore, a goal that might be easier to achieve might be rate control to 
an acceptable ventricular frequency.    
3.2 Rhythm or rate control 
Based on the studies performed in the general population, (Van Gelder et al 2002, Wyse et al 
2002) and postoperative atrial fibrillation, (Soucier et al 2003) and given the fact that a 
rhythm strategy with DC electrical cardioversion in critically ill cardiac surgery patients 
failed to show any benefit (Mayr et al 2003) and furthermore, chemical conversion is often 
accompanied by severe side effects or is contra-indicated, a rhythm control strategy is not 
recommend in critically ill patients, with the exception of those patients with life threatening 
cardiovascular collapse due to atrial fibrillation or in a setting of acute coronary syndrome. 
In these cases it is recommended to add an anti-arrhythmic drug in order to maintain sinus 
rhythm.  
This might introduce another problem, while most anti-arrhythmic drugs lower pressure or 
are contra-indicated in ischemic heart failure. 
Experience with rather new Vaughan-Williams class III anti arrhythmic drugs like ibutilide 
or nifekalant for chemical conversion is scarce. Ibitulide has been used in a few studies, 
(Bernard et al 2003, Hennersdorf et al 2002, Varriale et al 2000) but for the fact of  limited 
safety data, we cannot recommend treatment with ibitulide in the ICU setting.     
Few studies in critically ill patients have shown that just lowering ventricular rate by drugs 
that lower AV conduction and thereby contributing to more hemodyamic stability is  
effective for conversion to sinus rhythm.  Amiodarone intravenously is the most common 
used anti-arrrhythmic drug in this setting.   
Amiodarone,  a type III anti-arrhythmic drug with also  class II and IV effects , is well 
tolerated in hemodynamic unstable patients. Even patients with compromised left 
ventricular function can be safely treated with amiodarone. (Kumar 1996)  However, the 
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high rate of serious adverse reactions makes amiodarone very unpopular. These adverse 
reactions are usually seen in prolonged administration although, amiodarone-induced 
pulmonary toxicity (Daniels et al 1997, Donaldson et al 1997, Laprinsky et al 1993, Van 
Mieghem et al 1994) and acute liver failure (Bravo et al 2005) may also present within days 
or weeks. These short terms adverse reactions of amiodarone are not well studied and may 
be underdiagnosed in clinical trials, especially in critically ill patients, since these patients 
often have more than one reason to develop (multi) organ failure.  
Beta adrenergic receptor blockers or nondihydropyridine calcium channel blockers like 
verapamil are also widely used for lowering ventricular rate, however, in ICU setting, these 
drugs may further compromise hemodynamic state in critically ill patients.  
The use of magnesium has shown some promising results both in critically ill patients 
(Sleeswijk et al 2008, Moran et al 1995) as also in the general population presenting with new 
onset atrial fibrillation. (Gullenstad et al 1993)  However, the anti-arrhythmic effect of 
magnesium is not completely understood. A normal serum level of magnesium does not 
rule out an absolute magnesium deficiency since magnesium is mainly located intracellular. 
So, it is difficult to establish whether the anti-arrhythmic effects of magnesium are mainly 
due to repletion of intracellular hypomagnesiaor  the result of  the presumed effect on  Na-
K-ATP-ase (Dyckner 1980, Ebel 1983) or the effect of blocking  of calcium channels. (White et 
al 1989) However, magnesium seems to be effective in patients with both a low and normal 
level of serum magnesium. (Eray et al 2000) The optimal dosage of magnesium has not yet 
been establish. There are different regimens used in clinical trials, which may explain the 
difference in success of the treatment.            
The facts that hypomagnesia is frequently seen in critically ill patients (Ryzen et al 1985) and 
that hypomagnesia is associated with increased mortality (Chernow et al 1989), in 
combination with the positive effects of magnesium seen on both ventricular and 
supraventricular arrhythmia, (Toraman et al 2001, Gullenstad et al 1993, Sleeswijk et al 2008, 
Moran et al 1995, Chiladakis et al 2001, Hays et al 1994, Jensen et al 1997) in the absence  of 
serious adverse effects,  and furthermore combined with the low cost, the prophylactic effect 
on pro-arrhythmia, (Caron et al 2003), the synergistic effect with anti-arrhythmic drugs 
(Kalus et al 2003) and the reduction for the need of potential toxic anti-arrhythmic, 
(Sleeswijk et al 2008) justify its use in all critically ill patients with atrial fibrillation. Of 
course, serum levels should be monitored, especially in those with renal failure, to prevent 
toxicity of hypermagnesia. Although there are different regimes used in clinical trials, we 
suggested a treatment regime with a bolus magnesium of 0.037 gram/kg body weight 
within 15 minutes followed by a continuous infusion of 0.025 gram/kg body weight / hour. 
(Sleeswijk et al 2008, Moran et al 1995)           
Digoxin is one of the oldest anti-arrhythmic drugs with positive inotropic and negative 
dromotropic effect. However, its dromotropic effect is very disappointing, especially in the 
critically ill patients probably because the enhanced adrenergic state which is seen in these 
patients. (Falk et al 1987, Clemo et al 1998, Goldman et al 1975) Furthermore, digoxin has 
several serious side effects and the combination of rather ineffectiveness with safety matters 
makes digoxin not recommended in critically ill patients. 
Since inflammation plays an important crucial role in the pathophysiology of new onset 
atrial fibrillation in critically ill patients, it is tempting to use anti-inflammatory agents for 
the treatment and prevention of atrial fibrillation.  Glucocorticoids, (Whitlock et al 2008) 
statins, angiotensin converting enzyme inhibitor and 3 fatty acids (Guglin et al 2008) may 
have shown to be effective in preventing or termination atrial fibrillation by modulating the 
substrate. Due to the limited evidence and safety concerns these agents cannot yet be 
recommended for the treatment of new onset atrial fibrillation in critically ill patients.  
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AF= atrial fibrillation 
ACS= acute coronary syndrome 
Fig. 1. Treatment algorithm for new onset atrial fibrillation in critically ill patients.  
In summarize, the treatment of new onset atrial fibrillation in critically ill patients should 
start with the correction of precipitating factors and is further primarily aimed at a rate 
control strategy, starting with the infusion of magnesium. If rate control is not achieved we 
recommend amiodarone for the unstable patients and in hemodynamic stable patients a 
beta adrenergic receptor blocker of verapamil can be started. With this regime conversion to 
sinus rhythm will occur within 24 hours in most patients.  
4. Prevention of thrombo-embolic complications     
The risk for thrombo-embolic complication is increased in patients with atrial fibrillation 
lasting for more than 48 hours. Critically ill patients are at risk for thrombo-embolic 
complications due to their underlying disease and immobility. The formation of thrombi in 
atrial fibrillation is the result of the combination of blood coagulation status, vessel wall 
related factors and reduced blood flow. All these 3 factors are altered in favor of more easily 
development of thrombi in critically ill patients. Furthermore, inflammation, usually present 
in critically ill patients, might enhance development of thrombosis. However, critically ill 
patients also have a high risk of bleeding complications due to coagulation disorders (Levi 
et al 2006) or the need for invasive procedures during their stay in the ICU.    
In each patient the benefit of stroke prevention must be weighed against the risk of 
bleeding. Although data are lacking, we tend to mention that the CHADS2 risk calculator 
for thrombo-embolic complication in atrial fibrillation cannot be applied in the critically ill. 
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In case of persistent atrial fibrillation for at least 48 hours, one should consider starting 
anticoagulant therapy in critically patients. Due to the high bleeding risk we recommend 
treatment with unfractionated heparin or short acting low molecular weight heparin.     
5. Prognosis  
Treatment with magnesium and or drugs that lower AV node conduction is in most case 
effective to restore sinus rhythm within 24 hours. Recurrence rate and long term outcome 
has not been studied in critically ill patients. New onset atrial fibrillation in critically ill 
patients is associated with increased mortality, morbidity and prolonged ICU stay. 
(Sleeswijk et al 2007)  However, a causal link between atrial fibrillation and mortality has not 
yet been found. Atrial fibrillation may simply be a marker of severity of illness rather than 
an independent contributor of mortality.         
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